NCAM1 and small cell lung carcinoma: Another CAR-T cell construct developed by Crossland et al. in 2018 [43] targeted CD56, also named NCAM-1 (neuronal cell adhesion molecule 1), a glycoprotein highly expressed on the surface of malignancies with a neuronal or neuroendocrine origin, including SCLC, independently of HLA expression.